Clinical Data on 37 Patients Autografted for CML With Busulfan Only as Cytoreduction
| A . | No. of Patients (%) . |
|---|---|
| Disease status at autograft | |
| CP | 28 (76) |
| CP2 | 2 (5) |
| AP | 6 (16) |
| BC | 1 (3) |
| Autograft method | |
| BM | 5 (14) |
| PBSC | 8 (22) |
| Mobilized PBSC | 11 (30) |
| MYB antisense-150 | 4 (11) |
| Vancouver-151 | 9 (24) |
| A . | No. of Patients (%) . |
|---|---|
| Disease status at autograft | |
| CP | 28 (76) |
| CP2 | 2 (5) |
| AP | 6 (16) |
| BC | 1 (3) |
| Autograft method | |
| BM | 5 (14) |
| PBSC | 8 (22) |
| Mobilized PBSC | 11 (30) |
| MYB antisense-150 | 4 (11) |
| Vancouver-151 | 9 (24) |
| B . | Median . | Range . |
|---|---|---|
| Age at autograft (yr) | 45.3 | (20.8-56.7) |
| Duration of disease at autograft (mos) | 30.2 | (7.2-105.0) |
| Nucleated cell dose (×108/kg) | 3.8 | (0.7-12.3) |
| Duration of neutropenia (d) | 12.5 | (2-110) |
| Duration of platelet support (d) | 23 | (0-158) |
| Hospital stay (days) | 35 | (13-124) |
| Interval from autograft to restarting anti-leukemic therapy (mos) | 4.5 | (0.8-19.8) |
| B . | Median . | Range . |
|---|---|---|
| Age at autograft (yr) | 45.3 | (20.8-56.7) |
| Duration of disease at autograft (mos) | 30.2 | (7.2-105.0) |
| Nucleated cell dose (×108/kg) | 3.8 | (0.7-12.3) |
| Duration of neutropenia (d) | 12.5 | (2-110) |
| Duration of platelet support (d) | 23 | (0-158) |
| Hospital stay (days) | 35 | (13-124) |
| Interval from autograft to restarting anti-leukemic therapy (mos) | 4.5 | (0.8-19.8) |
| C . | Median . | 95% CI . |
|---|---|---|
| Survival from 1st autograft (yr) | 3.4 | (1.7-5.9) |
| Survival from diagnosis (yr) | 6.3 | (5.7-6.9) |
| C . | Median . | 95% CI . |
|---|---|---|
| Survival from 1st autograft (yr) | 3.4 | (1.7-5.9) |
| Survival from diagnosis (yr) | 6.3 | (5.7-6.9) |
A: Disease status and autograft method; B: Age, duration of disease, and autograft details; C: Survival.
Abbreviations: CP, chronic phase; CP2, second chronic phase after blastic transformation; AP, accelerated phase; BT, blastic transformation; BM, bone marrow; PBSC, peripheral blood stem cells.
Autograft performed with marrow cells incubated in vitro with a MYB antisense oligomer.
Autograft performed with marrow cells incubated for 10 days in liquid culture.